FindTrial
Sign In

recombinant flt3 ligand

BIOLOGICAL7 trials

Sponsors

Duke University, Northwestern University, Eastern Cooperative Oncology Group, National Cancer Institute (NCI), University of Southern California

Conditions

Anatomic Stage IV Breast Cancer AJCC v8Basal Cell CarcinomaBone SarcomaBreast CancerColorectal CancerCutaneous MelanomaCutaneous Squamous Cell CarcinomaKidney Cancer

Phase 1

Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma
TerminatedNCT00005787
Northwestern UniversityLymphoma, Neutropenia
Start: 1999-09-30End: 2002-01-31Updated: 2012-06-01
Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer
CompletedNCT00006225
Northwestern UniversityBreast Cancer, Leukemia, Lymphoma +2
Start: 1999-11-30End: 2004-01-31Updated: 2012-06-06
Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
CompletedNCT00020540
National Cancer Institute (NCI)Kidney Cancer, Melanoma (Skin)
Start: 2001-03-31Updated: 2015-04-30
Flt3L in Treating Patients With Metastatic Colorectal Cancer
CompletedNCT00003431
Duke UniversityColorectal Cancer, Metastatic Cancer
Start: 1998-06-30End: 2001-05-31Updated: 2013-03-05
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
Active, not recruitingNCT04616248
University of Southern CaliforniaAnatomic Stage IV Breast Cancer AJCC v8, Basal Cell Carcinoma, Bone Sarcoma +10
Start: 2023-01-09End: 2028-01-09Updated: 2026-01-07

Phase 2

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
CompletedNCT02129075
National Cancer Institute (NCI)Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary +9
Start: 2014-04-09End: 2018-05-18Updated: 2021-11-16

Phase 3

flt3L in Treating Patients With Acute Myeloid Leukemia
CompletedNCT00006223
Eastern Cooperative Oncology GroupLeukemia
Start: 2000-07-31End: 2007-01-31Updated: 2013-06-24

Related Papers

Abstract A052: Safety, immunogenicity and resistance of <i>in situ</i> Immunomodulation with CDX-301, radiotherapy, CDX-1140, and Poly-ICLC in patients with unresectable and metastatic solid tumors: a phase 1 trial
Cancer Immunology Research2026-02-18
A phase 1 trial in progress for in situ immunomodulation with CDX-301, radiation therapy, poly-ICLC, and CDX-1140 in patients with unresectable and metastatic solid tumors.
Journal of Clinical Oncology2024-06-013 citations
A Pilot Study of Pembrolizumab Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma
Cancer Control2024-01-011 citations
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets.
2020-11-1688 citations
A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand.
Journal of Clinical Oncology2016-05-2019 citations